The FDA issued warning letters to two companies this month, alleging FD&C Act violations stemming from marketing new drugs without approval. Companies marketing CBD products should be careful not to market OTC drugs containing CBD.
The post FDA Issues Warning Letters on Marketing and Sale of OTC CBD Products appeared first on Cannabis Industry Journal.
In this three-part series, cannabis lawyer and compliance expert Todd Feldman takes a look at how laws shape California’s supply chain, constrains business practices and affects the cost of doing business. In part one, we find that the regulated cannabis market can only be understood in relation to the previous medical market as well as the ongoing “traditional” market.
The post Learning from the First Wave Part 1: How Law Shapes the California Cannabis Industry appeared first on Cannabis Industry Journal.
A new California Proposition 65 mandate took effect on January 3, requiring health warning labels for all cannabis products sold in the state. Failure to comply with the requirements can and will result in enforcement against cannabis producers and sellers, resulting in hefty penalties.
The post CA Health and Safety Warning Laws Have Changed: Are You In Compliance? appeared first on Cannabis Industry Journal.